A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
The main objective of this study is to evaluate the safety, reactogenicity, and immunogenicity of the mRNA-1647 vaccine administered according to a 3-study injection schedule in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive Japanese adults 18 to 40 years of age in the United States.
Epistemonikos ID: af112ce508449546adb884afcc1f045bc5f84e5a
First added on: Oct 02, 2023